Summary
The episode works through what the crossover designs of the 2016 psilocybin trials in people with cancer can show about how long benefit lasts, and explains that Special Access Program authorizations in Canada are case-by-case decisions about individual patients. Sarah and Kiffer read the dated, company-reported phase 3 results for COMP360 and for an LSD tablet, and calculate a number needed to treat for remission that is more than twice the one for response in the same trial. A teaching reanalysis of the published ELEKT-D counts shows how unequal withdrawals before treatment can make an apparently cautious analysis favour one arm, while the noninferiority conclusion holds under a worst-case assumption. After a content note, the hosts use the rule of three to show what zero serious adverse events in small trials leaves open, and they separate faster relief of depressive symptoms from reductions in suicidality in the esketamine trials. They close by debating whether moderate or very low certainty better describes the pooled evidence for psilocybin in depression, given functional unblinding.